首页> 美国卫生研究院文献>Journal of Histochemistry and Cytochemistry >Aberrant Expression of Osteopontin and E-Cadherin Indicates Radiation Resistance and Poor Prognosis for Patients with Cervical Carcinoma
【2h】

Aberrant Expression of Osteopontin and E-Cadherin Indicates Radiation Resistance and Poor Prognosis for Patients with Cervical Carcinoma

机译:骨桥蛋白和E-钙黏着蛋白的异常表达表明宫颈癌患者的抗辐射性和预后不良

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Radiotherapy is the first-line treatment for all stages of cervical cancer, whether it is used for radical or palliative therapy. However, radioresistance of cervical cancer remains a major therapeutic problem. Consequently, we explored if E-cadherin (a marker of epithelial-mesenchymal transition) and osteopontin could predict radioresistance in patients with locally advanced cervical squamous cell carcinoma (LACSCC). Patients were retrospectively reviewed and 111 patients divided into two groups (radiation-resistant and radiation-sensitive groups) according to progression-free survival (PFS). In pretreated paraffin-embedded tissues, we evaluated E-cadherin and osteopontin expression using immunohistochemical staining. The percentage of patients with high osteopontin but low E-cadherin expression in the radiation-resistant group was significantly higher than those in the radiation-sensitive group (p<0.001). These patients also had a lower 5-year PFS rate (p<0.001). Our research suggests that high osteopontin but low E-cadherin expression can be considered as a negative, independent prognostic factor in patients with LACSCC ([Hazard ratios (95% CI) 6.766 (2.940, 15.572)], p<0.001).
机译:放射疗法是子宫颈癌所有阶段的一线治疗,无论是用于根治性治疗还是姑息治疗。然而,子宫颈癌的放射线抗性仍然是主要的治疗问题。因此,我们探讨了E-钙粘蛋白(上皮-间质转化的标志物)和骨桥蛋白是否可以预测局部晚期宫颈鳞状细胞癌(LACSCC)患者的放射抵抗。回顾性检查患者,根据无进展生存期(PFS)将111例患者分为两组(抗辐射组和辐射敏感组)。在预处理的石蜡包埋的组织中,我们使用免疫组织化学染色评估了E-钙黏着蛋白和骨桥蛋白的表达。抗辐射组骨桥蛋白高但E-钙粘蛋白表达低的患者百分比显着高于辐射敏感组(p <0.001)。这些患者的5年PFS率也较低(p <0.001)。我们的研究表明,骨桥蛋白高而E-钙黏着蛋白低表达可被认为是LACSCC患者的阴性独立预后因素([危险比(95%CI)6.766(2.940,15.572)],p <0.001)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号